Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer

被引:0
|
作者
不详
机构
关键词
D O I
10.2165/00042310-200723050-00001
中图分类号
学科分类号
摘要
Disease-free survival improved and the risk of contralateral breast cancer decreased in postmenopausal women with hormone receptor-positive early breast cancer who switched to adjuvant exemestane after 2-3 years of tamoxifen to complete 5 years' adjuvant antiestrogen therapy relative to patients who continued tamoxifen. Exemestane and tamoxifen have different tolerability profiles, which offers some potential advantages and disadvantages. © 2007 Adis Data Information BV. All rights reserved.
引用
收藏
页码:1 / 4
页数:3
相关论文
共 50 条